This inventor holds 4 USPTO granted patents and 7 published patent applications and 1 EPO patent. Top assignee: Incyte Corporation. Active years: 2020-2024.
Company Filing History:
Years Active: 2020-2024
Title: Onur Atasoylu: Innovator in JAK2 Inhibitors
Introduction
Onur Atasoylu is a notable inventor based in Wilmington, DE (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target specific variants of JAK2, a protein associated with various diseases, including cancer. With a total of four patents to his name, Atasoylu's work is paving the way for new therapeutic options.
Latest Patents
Atasoylu's latest patents include innovative compounds that serve as JAK2 V617F inhibitors. The first patent focuses on substituted pyrrolo[2,3-d]pyrimidine compounds, which are designed to modulate the activity of the V617F variant of JAK2. These compounds hold promise for the treatment of various diseases, particularly cancer. The second patent details tricyclic urea compounds that also target the V617F variant of JAK2, further contributing to the potential treatment landscape for cancer patients.
Career Highlights
Atasoylu is currently associated with Incyte Corporation, a leading biopharmaceutical company. His work at Incyte has allowed him to collaborate with other talented scientists and contribute to groundbreaking research in the field of oncology. His dedication to innovation and research has established him as a key figure in the development of new therapeutic agents.
Collaborations
Atasoylu has worked alongside esteemed colleagues such as Wenqing Yao and Cheng-Tsung Lai. Their collaborative efforts have enhanced the research and development of JAK2 inhibitors, showcasing the importance of teamwork in scientific advancements.
Conclusion
Onur Atasoylu's contributions to the field of medicinal chemistry, particularly through his patents on JAK2 inhibitors, highlight his role as an influential inventor. His work continues to inspire advancements in cancer treatment and showcases the potential of innovative research in improving patient outcomes.